Please assess the completion status of the following clinical trial:

Trial Title: Esmolol for Treatment of Perioperative Tachycardia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or Females~2. Age \> 40y/o~3. Scheduled high risk (ASA II-IV) non-cardiac surgery with anticipated 12 hour post-operative ICU care~4. Written informed consent~5. Patients on a stable chronic oral beta-blocker therapy~6. Revised Cardiac Risk Index 1(below) Cardiac Risk Index 1 or greater (below)~   * a history of coronary disease~  * a history of congestive heart failure~  * a history of treated diabetes~  * a history of cerebrovascular disease~  * a history of chronic renal failure~Exclusion Criteria:~1. Active bleeding~2. Untreated left main disease~3. Active cardiac condition (eg unstable angina pectoris, acute exacerbation of CHF, serious arrhythmias, symptomatic valve disease)~4. Preoperative positive troponin T~5. Contraindication for esmolol use~6. Previous allergy or intolerance to esmolol~7. Cancer with an expected life expectancy \< 6 months~8. Pregnancy or lactating or planning to become pregnant~9. Failure to provide informed consent, unable to understand or follow instructions.~10. History of drug allergy or idiosyncrasy to beta-adrenergic drugs~11. Recent history (within 1 year) of drug or alcohol abuse~12. Patients with a Pacemaker~13. Abnormal liver function Child-Pugh - B~14. Body Mass Index \> 45~15. Reactive airway disease (defined as a history of hospitalization with status asthmaticus within the past one year)~16. Surgery scheduled to begin after 2pm

- Gender: ALL
- Minimum Age: 41 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- oral long acting beta blocker (Type: ACTIVE_COMPARATOR): oral administration of long acting beta blocker as standard of care on the day of surgery
- Esmolol infusion (Type: EXPERIMENTAL): given 30 minutes prior to induction up to 12 hours post-op

Based on this trial design, predict the completion outcome and termination type (if applicable).